Oncology - European Medical Journal

Continue

Oncology

Filter
9 Dec 2015

Deciding which of the available genomic tests to use

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in…
9 Dec 2015

Progress in the treatment of BRAF-mutant melanoma

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the…
9 Dec 2015

BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single…
9 Dec 2015

BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer…
9 Dec 2015

MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma

At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety…
9 Dec 2015

Involving patients in the use of their data

Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by NHS on a daily basis…
9 Dec 2015

2015 NCRI Cancer Conference highlights and new NCRI initiatives

Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference…
EMJ
9 Dec 2015

Epigenetic targets in cancer

Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer Research Institute (NCRI) Cancer…